QNRX

QNRX

USD

Quoin Pharmaceuticals Ltd. American Depositary Shares

$9.860-0.283 (-2.791%)

Цена в режиме реального времени

Healthcare
Биотехнология
Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$10.143

Максимум

$10.500

Минимум

$9.860

Объем

0.01M

Фундаментальные показатели компании

Рыночная капитализация

5.9M

Отрасль

Биотехнология

Страна

United States

Статистические данные торговли

Средний объем

0.31M

Биржа

NCM

Валюта

USD

52-недельный диапазон

Минимум $5.01Текущая $9.860Максимум $48.3

Связанные новости

GlobeNewswire

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025

ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan

Просмотреть больше
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025
GlobeNewswire

Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month 'Whole Body' Data Update from Ongoing Study

Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study TargetCurrent Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of ‘Whole Body'

Просмотреть больше
Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month 'Whole Body' Data Update from Ongoing Study
GlobeNewswire

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct. 21, 2025

Просмотреть больше
Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
GlobeNewswire

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million

ASHBURN, Va., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today

Просмотреть больше
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.